GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Cyclically Adjusted Book per Share

ENZN (Enzon Pharmaceuticals) Cyclically Adjusted Book per Share : $0.24 (As of Dec. 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Enzon Pharmaceuticals's adjusted book value per share for the three months ended in Dec. 2024 was $0.041. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.24 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Enzon Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -20.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -32.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -35.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Enzon Pharmaceuticals was 31.10% per year. The lowest was -42.10% per year. And the median was -0.30% per year.

As of today (2025-05-17), Enzon Pharmaceuticals's current stock price is $0.09322. Enzon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was $0.24. Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.39.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enzon Pharmaceuticals was 0.96. The lowest was 0.08. And the median was 0.19.


Enzon Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

The historical data trend for Enzon Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Cyclically Adjusted Book per Share Chart

Enzon Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.23 0.77 0.37 0.30 0.24

Enzon Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.30 0.28 0.27 0.24

Competitive Comparison of Enzon Pharmaceuticals's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Enzon Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enzon Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=0.041/133.1571*133.1571
=0.041

Current CPI (Dec. 2024) = 133.1571.

Enzon Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201503 0.832 99.621 1.112
201506 0.418 100.684 0.553
201509 0.377 100.392 0.500
201512 0.409 99.792 0.546
201603 0.443 100.470 0.587
201606 0.471 101.688 0.617
201609 0.488 101.861 0.638
201612 0.234 101.863 0.306
201703 0.248 102.862 0.321
201706 0.343 103.349 0.442
201709 0.196 104.136 0.251
201712 0.207 104.011 0.265
201803 0.200 105.290 0.253
201806 0.195 106.317 0.244
201809 0.183 106.507 0.229
201812 0.339 105.998 0.426
201903 0.271 107.251 0.336
201906 0.270 108.070 0.333
201909 0.143 108.329 0.176
201912 0.137 108.420 0.168
202003 0.131 108.902 0.160
202006 0.126 108.767 0.154
202009 0.117 109.815 0.142
202012 0.099 109.897 0.120
202103 0.093 111.754 0.111
202106 0.085 114.631 0.099
202109 0.076 115.734 0.087
202112 0.066 117.630 0.075
202203 0.055 121.301 0.060
202206 0.044 125.017 0.047
202209 0.037 125.227 0.039
202212 0.046 125.222 0.049
202303 0.041 127.348 0.043
202306 0.037 128.729 0.038
202309 0.034 129.860 0.035
202312 0.047 129.419 0.048
202403 0.044 131.776 0.044
202406 0.041 132.554 0.041
202409 0.037 133.029 0.037
202412 0.041 133.157 0.041

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Enzon Pharmaceuticals  (OTCPK:ENZN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Enzon Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.09322/0.24
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Enzon Pharmaceuticals was 0.96. The lowest was 0.08. And the median was 0.19.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Enzon Pharmaceuticals Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals Inc is positioned as a public company acquisition vehicle, where the Company can become an acquisition platform and more fully utilize its net operating loss carryforwards and enhance stockholder value.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121

Enzon Pharmaceuticals Headlines

From GuruFocus

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-09-2010

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2009

Enzon Inc. Reports Operating Results (10-K)

By gurufocus 10qk 03-16-2011

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-04-2010

Enzon Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-10-2010

Top Micro-Cap Picks From the Gurus

By Sheila Dang Sheila Dang 06-23-2015

Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals

By Sydnee Gatewood Sydnee Gatewood 12-02-2016